

OTC Markets Group

Joining us today is Douglas Drysdale the CEO of Cybin that trades on our OTCQB Venture Market under the ticker CLXPF. Cybin is a life sciences company at the forefront of the revolution in mental health therapeutics. And is developing a new class of psychedelic medicines and treatment protocols with the goal becoming the leader in psychedelic therapeutics for mental. Well-being Doug. Thanks so much for joining us today. So Doug tell us about your experience in the healthcare sector.

Doug Drysdale

Thanks for having me Cecilia.

OTC Markets Group

And how you got involved with Sabin.

Doug Drysdale

Sure? Yeah I've been in the healthcare space my entire career actually 30 years or so um, the last dozen years. The CEO of 4 different companies, 2 public 2 private 2 startups 2 turnaround so a bit of a mix of experiences. But I really got started very young right out of high school I worked in a hospital lab by Chemistry lab and yeah in the middle of the night testing blood samples and the bulk of those samples are from at that time of day from teenage overdoses or from suicide attempts. So depression. And addiction so which is quite ah, an awakening at that age and also over the years I've had family members and friends that have suffered from a depression addiction even suicide. So so when this opportunity came along to really contribute to moving the science forward in the space. It was too good to miss.

OTC Markets Group

Excellent to hear so with a mission to revolutionize Healthcare talk about Cybin's unique and nontraditional approach to treat mental and neurological disorders.

Doug Drysdale

Well to be successful in drug development. You've really got to have 3 things 1 is differentiated science and IP and the second is a strong balance sheet unfortunately drug development is quite expensive. And you need an experienced team that can execute so we're very fortunate Cybin to have all 3 of those our unique approach to creating shorter acting and more scalable treatments for depression and addiction using drug duration technology from where we're due

Podcast

toating psychedelics. That's covered by 10 patent filings. So we're expecting strong protection. We're well capitalized. We've had over 4 oversubscribe rounds raising around for \$90000000 over the last year or so and primarily from us biotech funds and then we have the only team in the in the space that has actually developed. And approved psychedelic treatment with over sixty FDA programs under their bells. So we're in great shape to move the signs forward.

OTC Markets Group

And why do you think there's been a recent increase in experimentation and curiosity around psychedelics in the last several years. Yeah.

02:50.99

Doug Drysdale

Yeah, it's true I think we've become more open-minded to these less traditional treatments. But in the last year and a half or so this pandemic has there's not only increased the prevalence of mental illness and I saw a study yesterday in the lancet that said something like 1 in 3 covid survivors would go on to develop some form of a mental almost primarily anxiety which I guess is not a surprise but I guess 1 thing that's come out of this pandemic also has been our increased willingness to talk about the scale of the issue and the need. For treatments really nothing. There's not much out there that works well for depression and addiction and so this new awareness I think opens up our minds to exploring new ways to address the problem and let's face it depression and addiction are pretty much ubiquitous these days. So when we see really compelling evidence for the powerful efficacy of these psychedelic molecules in depression and addiction. You know with many patients getting remission for five or six months at a time from just 1 or 2 doses which is completely life changing then it's not really surprising to me that there's a great interest in. Developing this potential further.

OTC Markets Group

And how are psychedelics differentiated from Cannabis and other conventional drugs as an alternative medicinal solution for mental health.

Doug Drysdale

Yeah I can see people drawing the parallels. But when you look back now the kind of much hailed pharmaceutical potential for cannabinoids has been pretty disappointing I many companies have programs that they started that have now been shut down. And the challenge we can have on is that they appear to work at best as an entourage. So a combination of several different cannabinoids working together and that creates a couple of challenges that the first is figuring out.

Podcast

What's the right combination and proportions from hundreds of different cannabinoids. So you've got many permutations. And then a second which is probably a bit more difficult one is how do you design? clinical studies to demonstrate the benefit because when you're looking at combinations you have to show benefit over the individual components themselves and I can tell you that drugs with drugs with just 2 ingredients are challenging enough. And there are hardly any drugs that are approved that have even 3 ingredients because of the complexity. It's a really big hurdle thankfully with psychedelics. There's tons of evidence of safety and efficacy going back almost eighty years now hundreds of studies looking at this single well defined molecules. And our job of course is now to take those smaller academic studies and translate them into larger randomized placebo control clinical trials and take them through yeah the FDA.

OTC Markets Group

What Milestones and partnerships do you anticipate for Cybin in the coming years?

Doug Drysdale

Well, we recently just announced that we've selected alcohol use disorder as the initial target indication for our novel duoritinated tryptamine c y b Zero zero three a U d is very large issue alcohol use disorder is the third leading preventable cause of death in the us and and kills one three million people globally each year so we expect to file on I and d with the FDA before the end of 2021 to begin first in man safety studies which is very exciting big milestone for us and we're also expecting to start a phase two study for depression in the near future using our sublingual film formulation of psilocybin for amazing depressive disorder. So. Those are some really big clinical milestones outside of our clinical programs. We've got a very active licensing and m and a effort ongoing seeking to build out the various verticals of our business over the next twelve months or so.

OTC Markets Group

And Cybin began trading on the OTCQB Venture Market earlier this year and has also traded on laneo exchange in Canada how does cross trading on the OTCQB market enhance your investor strategy in the us and internationally.

Doug Drysdale

Yeah, having access to the OTCQB market has been great. Actually we've seen volumes on the OTC often x exceed those on the nio on many days. So the listing has really opened up our company to New US Investors we've got a foundation of great us institutional. Biotech investors but it's awesome to have now access to



Podcast

Cybin Inc

Season 5 | Episode 23

retailer investors as well.

07:23.20

OTC Markets Group

Well, it's been great talking with you Doug. Cybin trades under the symbol CLXPF on our OTCQB Venture Market.

07:25.81

Doug Drysdale

Thanks for having me Cecilia.



Podcast

Cybin Inc

Season 5 | Episode 23

**This is an autogenerated transcript and may contain typos.*